Infographic | November 15, 2021

Small Molecule Sterile Injectable Outsourcing Volume

Source: ISR Reports

In Q2 2021, ISR asked 57 respondents how many small molecule sterile injectable products they have on the market, the proportion of sterile injectable manufacturing that is outsourced and the number of CDMOs they use to complete the work. On average, respondents have 3.4 marketed biologic products, of which 67% of drug product manufacturing is outsourced and use an average of 3.3 CDMOs.  To learn how these proportions are predicted to change in the next five years, follow the link to the Sterile Injectable Market Outlook report preview. 

VIEW THE INFOGRAPHIC!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: